Elite Pharmaceuticals, Inc. primarily engages in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. Their drug delivery technology involves releasing a drug into the bloodstream or delivering it to a target site in the body over an extended period of time or at predetermined times.
| Revenue (Most Recent Fiscal Year) | $84.04M |
| Net Income (Most Recent Fiscal Year) | $-4.32M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.79 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 12.80 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 33.22 |
| Pre-Tax Margin (Trailing 12 Months) | -1.39% |
| Net Margin (Trailing 12 Months) | -10.26% |
| Return on Equity (Trailing 12 Months) | -9.88% |
| Return on Assets (Trailing 12 Months) | -4.72% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.23 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.44 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.09 |
| Inventory Turnover (Trailing 12 Months) | 2.67 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.04 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.01 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 1.07B |
| Free Float | 916.53M |
| Market Capitalization | $610.28M |
| Average Volume (Last 20 Days) | 1.44M |
| Beta (Past 60 Months) | 0.33 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 14.42% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.01% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |